Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer
January 10 2022 - 8:00AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company
developing transformative therapies for the treatment of cancer and
rare diseases, today announced the appointment of Jathin Bandari,
M.D., as Chief Medical Officer. Dr. Bandari is a practicing
urologic oncologist, recently serving at the University of
Rochester where he specialized in both minimally invasive urologic
oncology and advanced open pelvic retroperitoneal cancer surgery,
and where he maintains a faculty appointment. Dr. Bandari joined
Protara in April 2020 as Vice President, Head of Clinical
Development, and most recently was Interim Chief Medical Officer.
“We are thrilled for Dr. Bandari to expand his role with
Protara,” said Jesse Shefferman, Chief Executive Officer of Protara
Therapeutics. “His deep experience working with urologic cancer
patients is invaluable as we continue to advance our lead product
candidate, TARA-002, for the treatment of non-muscle invasive
bladder cancer (NMIBC).”
“Since joining Protara in April 2020, I have been fortunate to
work with a talented and innovative team, progressing TARA-002 as a
potential therapy for NMIBC, lymphatic malformations, and possibly
other cancers,” said Dr. Bandari. “I am thrilled to join this
exemplary team as Chief Medical Officer and work to advance
transformative therapies for people with cancer and rare
diseases.”
Dr. Bandari received his M.D. from Johns Hopkins University and
completed his urology residency at University of Pittsburgh Medical
Center. Following residency, he completed a Society of Urologic
Oncology fellowship at the University of Pittsburgh Medical Center.
He is an active member of the American Urological Association,
Society of Urologic Oncology, American Society of Clinical
Oncology, and Southwest Oncology Group. He has over 50
publications, national speakerships, textbooks, and grants.
About Protara Therapeutics, Inc.
Protara is committed to identifying and advancing transformative
therapies for people with cancer and rare diseases. Protara’s
portfolio includes its lead program, TARA-002, an investigational
cell-based therapy being developed for the treatment of non-muscle
invasive bladder cancer and lymphatic malformations, and IV Choline
Chloride, an investigational phospholipid substrate replacement
therapy for the treatment of intestinal failure-associated liver
disease. For more information, visit www.protaratx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Protara may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “designed,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words or expressions
referencing future events, conditions or circumstances that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such forward-looking statements include
but are not limited to, statements regarding Protara’s intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: statements regarding Protara’s
business strategy, Protara’s development plans for its product
candidates and expectations regarding the contribution of Dr.
Bandari’s experience in helping Protara achieve its strategic
objectives. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Factors
that contribute to the uncertain nature of the forward-looking
statements include risks and uncertainties associated with:
Protara’s development programs, including the initiation and
completion of non-clinical studies and clinical trials and the
timing of required filings with the FDA and other regulatory
agencies; the impact of the COVID-19 pandemic on Protara’s business
and the global economy; general market conditions; changes in the
competitive landscape; changes in Protara’s strategic and
commercial plans; Protara’s ability to obtain sufficient financing
to fund its strategic plans and commercialization efforts; the loss
of key members of management; and the risks and uncertainties
associated with Protara’s business and financial condition in
general, including the risks and uncertainties described more fully
under the caption "Risk Factors" and elsewhere in Protara's filings
and reports with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management's assumptions and estimates as of such date.
Protara undertakes no obligation to update any forward-looking
statements, whether as a result of the receipt of new information,
the occurrence of future events or otherwise, except as required by
law.
Company Contact:
Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com 646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024